Share This Page
Drug Price Trends for NDC 14539-0675
✉ Email this page to a colleague
Average Pharmacy Cost for 14539-0675
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| HYDROXYZINE PAM 50 MG CAP | 14539-0675-05 | 0.08327 | EACH | 2025-12-17 |
| HYDROXYZINE PAM 50 MG CAP | 14539-0675-01 | 0.08327 | EACH | 2025-12-17 |
| HYDROXYZINE PAM 50 MG CAP | 14539-0675-05 | 0.08506 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 14539-0675
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| HYDROXYZINE PAMOATE 50MG CAP | AvKare, LLC | 14539-0675-05 | 500 | 35.52 | 0.07104 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
rket Analysis and Price Projections for NDC 14539-0675
Introduction
The drug identified by NDC 14539-0675 corresponds to the medication [Insert drug name], a [specify drug class or indication] utilized predominantly in [specify treatment area, e.g., oncology, cardiology, neurology, etc.]. This report provides a comprehensive market analysis and price projection, considering current demand, competitive landscape, regulatory factors, and economic trends impacting pricing dynamics.
Product Overview and Regulatory Status
NDC 14539-0675 relates to [biosimilar, brand name, or generic]. The drug has achieved [approval status—e.g., FDA approval, biosimilar designation, orphan drug status, etc.], establishing a legal and regulatory framework for distribution and reimbursement. Its patent expiry date, exclusivity periods, and any recent regulatory updates shape its market positioning. [Insert specific regulatory milestones or deadlines.]
Current Market Landscape
Market Size and Growth Dynamics
The demand for [drug name] remains robust owing to [key factors such as prevalence of the target condition, unmet medical needs, or efficacy advantages]. According to recent industry reports, the [specific therapy area] market is projected to grow at a [X]% CAGR over the next [Y] years, fueled by [e.g., expanding indications, increased diagnosis rates, or technological innovations].
Key Competitors and Market Shares
The competitive environment comprises [list major players—brand name, biosimilar, generic versions]. The original innovator maintains a significant market share, but biosimilars and generics are gaining traction due to [cost advantages, regulatory approvals]. Notably, [competitor 1], introduced in [year], captured [X]% of the market, underscoring price sensitivity among payers and providers.
Pricing Trends and Historical Data
Historically, [the drug] has been priced at $[X] per [unit, dose, vial, etc.]. The price has experienced [steady increase, stabilization, or decline] driven by [patent expiry, healthcare policies, or market entry of competitors]. The recent entry of [biosimilar or generic] has exerted downward pressure, leading to a [X]% reduction in acquisition costs over the past [Y] years.
Factors Influencing Price Projections
Regulatory Landscape
Regulatory decisions considerably impact pricing trajectories. The approval of biosimilars under pathways like the FDA’s 351(k) significantly enhances competition, pressuring tradenames' prices. Furthermore, national healthcare policies promoting biosimilar adoption aim to accelerate price reductions.
Reimbursement and Payer Dynamics
Reimbursement policies, including Medicaid and Medicare frameworks, influence actual transaction prices. The shift toward value-based care incentivizes cost-efficient therapies, likely constraining future price increases. Payer negotiations and formulary placements further dictate market prices and accessibility.
Patent and Exclusivity Expiry
The expiration date of patent protections for [brand name or original innovator] is a critical determinant. Once exclusivity lapses, biosimilar and generic competitors drive prices down substantially, often by [X]% to Y]% within the first few years. The timing of upcoming patent cliffs is, therefore, central to price projections.
Market Penetration of Biosimilars and Generics
Biosimilars in particular have demonstrated rapid market penetration in key regions like the US, EU, and Asia. Factors such as [manufacturing costs, acceptance by clinicians, regulatory incentives] influence how quickly these alternatives capture market share, impacting overall pricing.
Technological and Manufacturing Advances
Advances reducing production costs or improving drug stability may enable lower pricing. Conversely, unique formulation requirements or supply chain complexities could maintain or elevate costs.
Price Projection Scenarios
| Scenario | Assumptions | Projected Price Trend | Timeframe | Commentary |
|---|---|---|---|---|
| Conservative | Patent remains intact; biosimilar entry delayed; modest uptake. | Slight decrease or stabilization | Next 3–5 years | Prices will gradually decline, influenced by moderate biosimilar competition. |
| Moderate | Patent expiry within 2–3 years; biosimilar approval begins; healthcare policies favor cost savings. | Significant decline | 1–3 years | Rapid price erosion expected following biosimilar market entry. |
| Optimistic (Low-price) | Rapid biosimilar adoption coupled with regulatory incentives; increased healthcare pressure for affordability. | Substantial reduction | 1 year | Abundant biosimilar options could slash prices by over 50%. |
| Pessimistic (High-price) | Patent extension, limited biosimilar development, higher demand. | Price stabilization or slight increase | Next 5+ years | Market maintains higher price levels, driven by limited competition. |
Strategic Implications for Stakeholders
- Pharmaceutical Companies: Investing in biosimilar development and engaging in aggressive pricing strategies could capture market share early post-patent expiration. Patents and exclusivity management remain vital.
- Payers: Prioritize formulary placements favoring biosimilars to reduce costs, influencing overall price trends.
- Healthcare Providers: Embrace biosimilar options where evidence supports comparable efficacy; this can influence market prices favorably.
- Investors: Monitor patent expiry dates, biosimilar regulatory pathways, and regional adoption trends for optimal portfolio positioning.
Key Takeaways
- Market growth for [drug name] is poised for acceleration, driven by rising demand in [indication] and increased adoption of biosimilars.
- Patent expiry timelines and biosimilar approvals will be pivotal in defining near-term price trajectories. Expect significant price reductions post-patent expiration.
- Regulatory environments across regions increasingly favor biosimilar entry, amplifying competitive pressure and downward pricing momentum.
- Reimbursement policies are shifting toward valuing cost-effective therapies, favoring biosimilars and generics, further constraining prices.
- Manufacturing innovations may influence price stability or decreases, but initial reductions are primarily driven by market competition.
Frequently Asked Questions (FAQs)
1. When is patent expiry for NDC 14539-0675, and how will it impact prices?
Patent expiry is anticipated in [year], opening the market to biosimilars and generics, which are projected to cause substantial price declines within the subsequent [Y] years.
2. What are the key competitors for this drug, and how do they influence pricing?
Major competitors include [name biosimilars or generics], which have captured [X]% of the market post-entry, exerting downward pressure on prices through increased competition.
3. How do regulatory policies in major markets affect the pricing of this drug?
Regulations promoting biosimilar approval—such as FDA’s biosimilar pathway—accelerate market entry, fostering competitive pricing and potential discounts of [X]% or more.
4. What are the main economic factors influencing future prices?
Key factors include healthcare reimbursement models, biosimilar adoption rates, manufacturing costs, and regional pricing regulations, all of which converge to shape the price trajectory.
5. Is there potential for upward price movement or stabilization?
In scenarios where patent protections extend or biosimilar adoption is slow due to regulatory or clinical barriers, prices may stabilize or even experience modest increases driven by demand and limited competition.
Sources
- [Insert authoritative industry report or regulatory agency data]
- [Insert recent market analysis or healthcare economics studies]
- [Insert peer-reviewed publications or journal articles]
In conclusion, the market outlook for [drug name] (NDC 14539-0675) indicates a downward trajectory influenced by patent expiration, biosimilar approval, and healthcare policy shifts. Stakeholders should strategize accordingly to optimize value, mitigate risks, and leverage emerging opportunities within this dynamic landscape.
More… ↓
